1
|
Akdag Y. Nanoparticle-containing lyophilized dry powder inhaler formulations optimized using central composite design with improved aerodynamic parameters and redispersibility. Pharm Dev Technol 2023; 28:124-137. [PMID: 36602194 DOI: 10.1080/10837450.2023.2166066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Objectives: The aim of this study was to improve the aerodynamic behavior and redispersibility of a lyophilized dry powder inhaler (DPI) formulation containing nanoparticles.Methods: Paclitaxel (PTX)-human serum albumin (HSA) nanoparticles were used as a model, and DPIs containing the nanoparticles were produced by lyophilization using different carriers and carrier ratios. A central composite design was employed to optimize the formulation. L-leucine and mannitol were chosen as independent variables, and mass median aerodynamic diameter (MMAD), emitted fraction, fine particle fraction (FPF), nanoparticle size, polydispersity index (PDI), zeta potential were selected as dependent variables.Results: The water content of DPIs was less than 5% for all DPIs. The cytotoxicity of the DPIs, determined using A549 cells, was due to PTX alone. Particle sizes of 204.3 ± 1.65 nm and 94.3-1353.0 nm were obtained before and after lyophilization, respectively. The developed method resulted in a reduction in the MMAD from 8.148 µm to 5.274 µm, an increase in the FPF from 17.63% to 33.60%, and an increase in the emitted fraction from 77.68% to 97.03%. The physico-chemical characteristics of the optimized formulation were also assessed.Conclusions: In conclusion, this study demonstrates that lyophilization can be used to produce nanoparticle-containing DPI formulations with improved redispersibility and aerodynamic properties.
Collapse
Affiliation(s)
- Yagmur Akdag
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey
| |
Collapse
|
2
|
Infrared Thermography for Monitoring of Freeze Drying Processes—Part 2: Monitoring of Temperature on the Surface and Vertically in Cuvettes during Freeze Drying of a Pharmaceutical Formulation. Pharmaceutics 2022; 14:pharmaceutics14051007. [PMID: 35631593 PMCID: PMC9144070 DOI: 10.3390/pharmaceutics14051007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 04/29/2022] [Accepted: 05/05/2022] [Indexed: 12/10/2022] Open
Abstract
The coupling of an infrared (IR) camera to a freeze dryer for monitoring of the temperature of a pharmaceutical formulation (sucrose/mannitol solution, 4:1%, m/m) during freeze-drying has been exploited further. The new development allows monitoring of temperatures simultaneously at the surface as well as vertically, (e.g., in depth) along the side using custom-made cuvettes. The IR camera was placed on the chamber roof of a process-scale freeze dryer. Monitoring of cuvettes containing the formulation took place from above where one side of each cuvette was equipped with a germanium window. The Ge-window was placed next to an IR mirror having a 45° angle. The long-wave infrared radiation (LWIR) coming from the inside of the cuvette was reflected upwards toward the IR camera. Accurate recording of the temperature along the cuvettes’ depth profile was therefore possible. Direct imaging from −40 °C to 30 °C took place every 60 s on the surface and on the side with a 2 × 2 mm resolution per IR pixel for 45 h resulting in 2700 thermograms. Results are presented for freeze-drying of a pharmaceutical formulation as a function of time and spatially for the entire side (depth) of the cuvette. As the sublimation process was progressing, the spatial resolution (84 IR pixels for the side-view and 64 pixels for the surface-view) was more than sufficient to reveal lower temperatures deeper down in the material. The results show that the pharmaceutical formulation (a true solution at the onset) dries irregularly and that the sublimation front does not progress evenly through the material. During secondary drying, potential evaporative cooling of upper layers could be detected thanks to the high thermal and spatial resolution.
Collapse
|
3
|
Hester S, Ferenz KB, Eitner S, Langer K. Development of a Lyophilization Process for Long-Term Storage of Albumin-Based Perfluorodecalin-Filled Artificial Oxygen Carriers. Pharmaceutics 2021; 13:584. [PMID: 33923881 PMCID: PMC8073927 DOI: 10.3390/pharmaceutics13040584] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2021] [Revised: 04/14/2021] [Accepted: 04/17/2021] [Indexed: 12/23/2022] Open
Abstract
Every day, thousands of patients receive erythrocyte concentrates (ECs). They are indispensable for modern medicine, despite their limited resource. Artificial oxygen carriers (AOCs) represent a promising approach to reduce the need for ECs. One form of AOCs is perfluorodecalin-filled albumin-based nanocapsules. However, these AOCs are not storable and need to be applied directly after production. In this condition, they are not suitable as a medicinal product for practical use yet. Lyophilization (freeze drying) could provide the possibility of durable and applicable nanocapsules. In the present study, a suitable lyophilization process for perfluorodecalin-filled nanocapsules was developed. The nanocapsules were physicochemically characterized regarding capsule size, polydispersity, and oxygen capacity. Even though the perfluorodecalin-filled albumin-based nanocapsules showed a loss in oxygen capacity directly after lyophilization, they still provided a remarkable residual capacity. This capacity did not decline further for over two months of storage. Furthermore, the nanocapsule size remained unaltered for over one year. Therefore, the AOCs were still applicable and functional after long-term storage due to the successful lyophilization.
Collapse
Affiliation(s)
- Sarah Hester
- Institute of Pharmaceutical Technology and Biopharmacy, University of Muenster, Corrensstr. 48, 48149 Muenster, Germany;
| | - Katja Bettina Ferenz
- Institute of Physiology, University of Duisburg-Essen, University Hospital Essen, Hufelandstr. 55, 45122 Essen, Germany;
| | - Susanne Eitner
- Institute of Physiological Chemistry, University of Duisburg-Essen, University Hospital Essen, Hufelandstr. 55, 45122 Essen, Germany;
| | - Klaus Langer
- Institute of Pharmaceutical Technology and Biopharmacy, University of Muenster, Corrensstr. 48, 48149 Muenster, Germany;
| |
Collapse
|
4
|
Seifert I, Friess W. Improvement of arginine hydrochloride based antibody lyophilisates. Int J Pharm 2020; 589:119859. [DOI: 10.1016/j.ijpharm.2020.119859] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2020] [Revised: 09/02/2020] [Accepted: 09/03/2020] [Indexed: 01/06/2023]
|
5
|
Crystallizing amino acids as bulking agents in freeze-drying. Eur J Pharm Biopharm 2018; 132:70-82. [DOI: 10.1016/j.ejpb.2018.09.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Revised: 07/27/2018] [Accepted: 09/06/2018] [Indexed: 11/24/2022]
|
6
|
Horn J, Schanda J, Friess W. Impact of fast and conservative freeze-drying on product quality of protein-mannitol-sucrose-glycerol lyophilizates. Eur J Pharm Biopharm 2018. [PMID: 29522899 DOI: 10.1016/j.ejpb.2018.03.003] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
PURPOSE Mannitol/sucrose formulations are employed to generate lyophilizates for biopharmaceuticals with an elegant cake appearance. The aim of this study was to dry protein/mannitol/sucrose formulations as fast as possible without loss of cake appearance and protein stability. Glycerol was included as potential additional protein stabilizer. Three proteins (lysozyme and two monoclonal antibodies) at low and high concentration were analyzed comparing fast with conservative freeze-drying. METHODS Freeze-drying cycle development was carried out with mannitol/sucrose formulations. A product temperature (Tp) close to the Te of mannitol and clearly above the Tg' of sucrose was targeted. Protein formulations were exposed to the final fast lyophilisation process and to a conservative freeze-drying cycle. Lyophilizates were characterized by differential scanning calorimetry, Karl-Fischer titration and X-ray diffractometry. Additionally, macroscopic cake appearance and reconstitution times were evaluated. Protein stability was characterized by UV/Vis spectroscopy, light obscuration and size exclusion chromatography. RESULTS The fast freeze-drying cycle resulted in a primary drying time of 7 h (Tp: -10 °C) and a secondary drying time of 2 h in contrast to 47 h (Tp: -39 °C) and 12 h for the conservative cycle. Lyophilizates showed Tg values above 60 °C, a residual moisture level of 1%, reconstitution times of less than 35 s, δ-mannitol and elegant cake appearance. Mannitol/sucrose ratios below 4/1 did not lead to complete mannitol crystallization and were therefore not suitable for the selected process conditions. Characterisation of protein stability rendered low aggregation and particle levels for both, fast and conservative freeze-drying conditions. CONCLUSIONS It was shown that fast freeze-drying of mannitol/sucrose formulations above Tg' at a Tp of -10 °C resulted in good protein process stability and appropriate cake characteristics at maximum time reduction.
Collapse
Affiliation(s)
- Jacqueline Horn
- Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universität München, Munich, Germany
| | - Julia Schanda
- Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universität München, Munich, Germany
| | - Wolfgang Friess
- Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universität München, Munich, Germany.
| |
Collapse
|
7
|
Luis de Redín I, Boiero C, Martínez-Ohárriz MC, Agüeros M, Ramos R, Peñuelas I, Allemandi D, Llabot JM, Irache JM. Human serum albumin nanoparticles for ocular delivery of bevacizumab. Int J Pharm 2018; 541:214-223. [PMID: 29481946 DOI: 10.1016/j.ijpharm.2018.02.003] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2017] [Revised: 01/31/2018] [Accepted: 02/04/2018] [Indexed: 01/15/2023]
Abstract
Bevacizumab-loaded nanoparticles (B-NP) were prepared by a desolvation process followed by freeze-drying, without any chemical, physical or enzymatic cross-linkage. Compared with typical HSA nanoparticles cross-linked with glutaraldehyde (B-NP-GLU), B-NP displayed a significantly higher mean size (310 nm vs. 180 nm) and a lower negative zeta potential (-15 mV vs. -36 mV). On the contrary, B-NP displayed a high payload of approximately 13% when measured by a specific ELISA, whereas B-NP-GLU presented a very low bevacizumab loading (0.1 μg/mg). These results could be related to the inactivation of bevacizumab after reacting with glutaraldehyde. From B-NP, bevacizumab was released following an initial burst effect, proceeded by a continuous release of bevacizumab at a rate of 6 μg/h. Cytotoxicity studies in ARPE cells were carried out at a single dose up to 72 h and with repeated doses over a 5-day period. Neither bevacizumab nor B-NP altered cell viability even when repeated doses were used. Finally, B-NP were labeled with 99mTc and administered as eye drops in rats. 99mTc-B-NP remained in the eye for at least 4 h while 99mTc-HSA was rapidly drained from the administration point. In summary, HSA nanoparticles may be an appropriate candidate for ocular delivery of bevacizumab.
Collapse
Affiliation(s)
- Inés Luis de Redín
- Department of Pharmacy and Pharmaceutical Technology, NANO-VAC Research Group, University of Navarra, Spain
| | - Carolina Boiero
- UNITEFA-CONICET, Department of Pharmacy, Faculty of Chemical Sciences (FCQ-UNC), National University of Córdoba, Argentina
| | | | - Maite Agüeros
- Department of Pharmacy and Pharmaceutical Technology, NANO-VAC Research Group, University of Navarra, Spain
| | - Rocío Ramos
- Radiopharmacy Unit, Clínica Universidad de Navarra, Spain
| | - Iván Peñuelas
- Radiopharmacy Unit, Clínica Universidad de Navarra, Spain
| | - Daniel Allemandi
- UNITEFA-CONICET, Department of Pharmacy, Faculty of Chemical Sciences (FCQ-UNC), National University of Córdoba, Argentina
| | - Juan M Llabot
- UNITEFA-CONICET, Department of Pharmacy, Faculty of Chemical Sciences (FCQ-UNC), National University of Córdoba, Argentina
| | - Juan M Irache
- Department of Pharmacy and Pharmaceutical Technology, NANO-VAC Research Group, University of Navarra, Spain.
| |
Collapse
|
8
|
Ro J, Park C, Kim JT, Kim H, Lee YE, Yoo SY, Hong SC, Lee KB, Lee J. Enhancing Lysozyme Loading in Powderized Liposomes by Controlling Encapsulation Processes. B KOREAN CHEM SOC 2017. [DOI: 10.1002/bkcs.11164] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Affiliation(s)
- Jieun Ro
- College of Pharmacy; Chung-Ang University; Seoul 06974 Korea
| | - Changhee Park
- College of Pharmacy; Chung-Ang University; Seoul 06974 Korea
| | - Jeong Tae Kim
- College of Pharmacy; Chung-Ang University; Seoul 06974 Korea
| | - Hyeongmin Kim
- College of Pharmacy; Chung-Ang University; Seoul 06974 Korea
| | - Young-Eun Lee
- College of Pharmacy; Chung-Ang University; Seoul 06974 Korea
| | - Seung-Yup Yoo
- College of Pharmacy; Chung-Ang University; Seoul 06974 Korea
| | - Seong-Chul Hong
- College of Pharmacy; Chung-Ang University; Seoul 06974 Korea
| | - Kyung Bin Lee
- College of Pharmacy; Chung-Ang University; Seoul 06974 Korea
| | - Jaehwi Lee
- College of Pharmacy; Chung-Ang University; Seoul 06974 Korea
| |
Collapse
|
9
|
Jena S, Horn J, Suryanarayanan R, Friess W, Aksan A. Effects of Excipient Interactions on the State of the Freeze-Concentrate and Protein Stability. Pharm Res 2016; 34:462-478. [DOI: 10.1007/s11095-016-2078-y] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2016] [Accepted: 12/02/2016] [Indexed: 11/30/2022]
|
10
|
Process cycle development of freeze drying for therapeutic proteins with stability evaluation. JOURNAL OF PHARMACEUTICAL INVESTIGATION 2016. [DOI: 10.1007/s40005-016-0275-7] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
11
|
Ibrahim N, Ibrahim H, Sabater AM, Mazier D, Valentin A, Nepveu F. Artemisinin nanoformulation suitable for intravenous injection: Preparation, characterization and antimalarial activities. Int J Pharm 2015; 495:671-9. [PMID: 26383839 DOI: 10.1016/j.ijpharm.2015.09.020] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Revised: 09/10/2015] [Accepted: 09/11/2015] [Indexed: 02/02/2023]
Abstract
More than 40 years after its discovery, artemisinin has become the most promising antimalarial agent. However, no intravenous formulation is available due to its poor aqueous solubility. Here, we report the preparation, characterization, and in vitro and in vivo biological evaluation of biodegradable albumin-bound artemisinin nanoparticles. The nanoparticles were prepared by a combination of a bottom-up and a top-down processes and characterized by different spectroscopic techniques. The preparation process was optimized to develop a nanoformulation with the smallest possible diameter and good homogeneity suitable for intravenous injection enabling direct contact of artemisinin with infected erythrocytes. Chemically and physically stable artemisinin nanoparticles were obtained with excellent entrapment efficiency. In in vitro experiments, the artemisinin nanoformulation was interestingly more effective than non-formulated artemisinin. In Plasmodiumm falciparum-infected 'humanized' mice, the nanoparticles proved to be highly effective with 96% parasitemia inhibition at 10mg/kg/day, prolonging mean survival time without recrudescence. This nanoparticulate albumin-bound system allows the intravenous administration of artemisinin for the first time without harsh organic solvents or cosolvents with 100% bioavailability.
Collapse
Affiliation(s)
- Nehal Ibrahim
- Université de Toulouse, UPS, UMR 152 (PHARMA-DEV), F-31062 Toulouse Cedex 9, France; IRD, UMR 152, F-31062 Toulouse Cedex 9, France
| | - Hany Ibrahim
- Université de Toulouse, UPS, UMR 152 (PHARMA-DEV), F-31062 Toulouse Cedex 9, France; IRD, UMR 152, F-31062 Toulouse Cedex 9, France.
| | - Alicia Moreno Sabater
- Sorbonne Universités, UPMC Univ. Paris 06, CR7, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 Bd de l'hôpital, F-75013 Paris, France; INSERM, U1135, CIMI-PARIS, 91 Bd de l'hôpital, F-75013 Paris, France; CNRS, ERL 8255, CIMI-PARIS, 91 Bd de l'hôpital, F-75013 Paris, France
| | - Dominique Mazier
- Sorbonne Universités, UPMC Univ. Paris 06, CR7, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 Bd de l'hôpital, F-75013 Paris, France; INSERM, U1135, CIMI-PARIS, 91 Bd de l'hôpital, F-75013 Paris, France; CNRS, ERL 8255, CIMI-PARIS, 91 Bd de l'hôpital, F-75013 Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service Parasitologie-Mycologie, Paris, France
| | - Alexis Valentin
- Université de Toulouse, UPS, UMR 152 (PHARMA-DEV), F-31062 Toulouse Cedex 9, France; IRD, UMR 152, F-31062 Toulouse Cedex 9, France
| | - Françoise Nepveu
- Université de Toulouse, UPS, UMR 152 (PHARMA-DEV), F-31062 Toulouse Cedex 9, France; IRD, UMR 152, F-31062 Toulouse Cedex 9, France
| |
Collapse
|
12
|
Ibrahim N, Ibrahim H, Dormoi J, Briolant S, Pradines B, Moreno A, Mazier D, Legrand P, Nepveu F. Albumin-bound nanoparticles of practically water-insoluble antimalarial lead greatly enhance its efficacy. Int J Pharm 2014; 464:214-24. [PMID: 24412521 DOI: 10.1016/j.ijpharm.2014.01.001] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2013] [Revised: 12/28/2013] [Accepted: 01/02/2014] [Indexed: 01/08/2023]
Abstract
We recently showed that the indolone-N-oxides can be promising candidates for the treatment of chloroquine-resistant malaria. However, the in vivo assays have been hampered by the very poor aqueous solubility of these compounds resulting in poor and variable activity. Here, we describe the preparation, characterization and in vivo evaluation of biodegradable albumin-bound indolone-N-oxide nanoparticles. Nanoparticles were prepared by precipitation followed by high-pressure homogenization and characterized by photon correlation spectroscopy, transmission electron microscopy, differential scanning calorimetry and X-ray powder diffraction. The process was optimized to yield nanoparticles of controllable diameter with narrow size distribution suitable for intravenous administration, which guarantees direct drug contact with parasitized erythrocytes. Stable nanoparticles showed greatly enhanced dissolution rate (complete drug release within 30 min compared to 1.5% of pure drug) preserving the rapid antimalarial activity. The formulation achieved complete cure of Plasmodium berghei-infected mice at 25mg/kg with parasitemia inhibition (99.1%) comparable to that of artesunate and chloroquine and was remarkably more effective in prolonging survival time and inhibiting recrudescence. In 'humanized' mice infected with Plasmodium falciparum, the same dose proved to be highly effective: with parasitemia reduced by 97.5% and the mean survival time prolonged. This formulation can help advance the preclinical trials of indolone-N-oxides. Albumin-bound nanoparticles represent a new strategic approach to use this most abundant plasma protein to target malaria-infected erythrocytes.
Collapse
Affiliation(s)
- Nehal Ibrahim
- Université de Toulouse, UPS, UMR 152 (Laboratoire de pharmacochimie et pharmacologie pour le développement, Pharma-DEV), F-31062 Toulouse cedex 9, France; IRD, UMR 152, F-31062 Toulouse cedex 9, France
| | - Hany Ibrahim
- Université de Toulouse, UPS, UMR 152 (Laboratoire de pharmacochimie et pharmacologie pour le développement, Pharma-DEV), F-31062 Toulouse cedex 9, France; IRD, UMR 152, F-31062 Toulouse cedex 9, France.
| | - Jerome Dormoi
- Unité de Parasitologie, Institut de Recherche Biomédicale des Armées (IRBA), Le Pharo, 13262 Marseille, France; Unité de Recherche Maladies Infectieuses et Tropicales Emergentes (URMITE), Faculté de Médecine La Timone, Université Aix-Marseille, 13385 Marseille cedex 5, France
| | - Sébastien Briolant
- Unité de Parasitologie, Institut de Recherche Biomédicale des Armées (IRBA), Le Pharo, 13262 Marseille, France; Unité de Recherche Maladies Infectieuses et Tropicales Emergentes (URMITE), Faculté de Médecine La Timone, Université Aix-Marseille, 13385 Marseille cedex 5, France
| | - Bruno Pradines
- Unité de Parasitologie, Institut de Recherche Biomédicale des Armées (IRBA), Le Pharo, 13262 Marseille, France; Unité de Recherche Maladies Infectieuses et Tropicales Emergentes (URMITE), Faculté de Médecine La Timone, Université Aix-Marseille, 13385 Marseille cedex 5, France
| | - Alicia Moreno
- Université Pierre et Marie Curie-Paris 6, UMR S945, Paris, France; Institut National de la Santé et de la Recherche Médicale, U945, Paris, France
| | - Dominique Mazier
- Université Pierre et Marie Curie-Paris 6, UMR S945, Paris, France; Institut National de la Santé et de la Recherche Médicale, U945, Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service Parasitologie-Mycologie, Paris, France
| | - Philippe Legrand
- Institut Charles-Gerhardt, UMR 5253 CNRS/UM2/ENSCM/UM1, 8 rue de l'école Normale, 34296 Montpellier cedex 05, France
| | - Françoise Nepveu
- Université de Toulouse, UPS, UMR 152 (Laboratoire de pharmacochimie et pharmacologie pour le développement, Pharma-DEV), F-31062 Toulouse cedex 9, France; IRD, UMR 152, F-31062 Toulouse cedex 9, France
| |
Collapse
|